Positive CHMP Opinion For Mirabegron In Treatment Of Overactive Bladder Symptoms
Sunday, October 21, 2012 - 10:00
in Health & Medicine
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a marketing authorization for BETMIGA[ (mirabegron) for the symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. The opinion now needs ratification by decision of the European Commission which is expected within the next 74-90 days. If approved, mirabegron will be the first in a new class of OAB treatment, offering healthcare professionals an alternative option to antimuscarinics (currently the only licensed oral treatment option) when treating patients with OAB. read more